This year's Conference on Retroviruses and Opportunistic Infections broadened its lens from the lab to the ways that different strategies are, or might, have an impact in the context of people's complex lives.
Panelists at CROI 2018 painted a bleak picture of the scale of the country's addiction crisis, noting that the never-before-seen dynamics of the current drug epidemic require creative approaches to HIV treatment and prevention among people who inject...
A large case-control analysis reported an overall association between statin use and a reduced risk of virus-mediated cancers in HIV-positive people.
When is a pre-exposure prophylaxis (PrEP) failure actually a provider failure? And how do we tell the difference?
Gina Brown, M.D., shares her reflections on some of the many research findings about HIV prevention, care, and treatment for women and girls presented at CROI 2018.
Study highlights the need for PrEP and other HIV prevention strategies for pregnant women and new mothers in high-prevalence settings.
The Fair Pricing Coalition is working with pharmaceutical companies to ensure fair prices for new HIV drugs on par with those of older medications.
Presentations on women in research at this year's Conference on Retroviruses and Opportunistic Infections highlighted the lack of inclusion, offered ideas on how to remedy the situation, and showed how one woman moved from advocate to researcher.
Two video interviews with federal HIV leaders who share their perspectives about the science coming out of the conference and its implications for HIV prevention, care, and treatment.
The CDC has released new data at the Conference on Retroviruses and Opportunistic Infections (CROI) estimating that only a small percentage of people most at risk for HIV infection have actually been prescribed pre-exposure prophylaxis (PrEP).